Research programme: hepatitis C virus NS 5 protein inhibitors - Beta PharmaAlternative Names: NS5A inhibitors - Beta Pharma
Latest Information Update: 11 Nov 2016
At a glance
- Originator Beta Pharma
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Hepatitis C
Most Recent Events
- 09 Nov 2016 Early research in Hepatitis C in USA (unspecified route)